NASDAQ:CLSN - Celsion Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.96 +0.04 (+2.08 %) (As of 12/17/2018 07:56 AM ET)Previous Close$1.92Today's Range$1.84 - $1.9852-Week Range$1.68 - $3.48Volume78,162 shsAverage Volume94,251 shsMarket Capitalization$36.71 millionP/E Ratio-0.82Dividend YieldN/ABeta1.47 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey. Receive CLSN News and Ratings via Email Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSN Previous Symbol CUSIPN/A Webwww.celsion.com Phone609-896-9100 Debt Debt-to-Equity Ratio0.62 Current Ratio3.84 Quick Ratio3.84 Price-To-Earnings Trailing P/E Ratio-0.82 Forward P/E Ratio-1.46 P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales73.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.66 per share Price / Book1.18 Profitability EPS (Most Recent Fiscal Year)($2.39) Net Income$-20,400,000.00 Net Margins-4,282.33% Return on Equity-104.30% Return on Assets-48.49% Miscellaneous Employees21 Outstanding Shares18,730,000Market Cap$36.71 million OptionableOptionable Celsion (NASDAQ:CLSN) Frequently Asked Questions What is Celsion's stock symbol? Celsion trades on the NASDAQ under the ticker symbol "CLSN." When did Celsion's stock split? How did Celsion's stock split work? Shares of Celsion reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split. How were Celsion's earnings last quarter? Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings data on Thursday, November, 15th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.04. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 4,282.33% and a negative return on equity of 104.30%. View Celsion's Earnings History. When is Celsion's next earnings date? Celsion is scheduled to release their next quarterly earnings announcement on Tuesday, March 26th 2019. View Earnings Estimates for Celsion. What price target have analysts set for CLSN? 2 equities research analysts have issued 1-year price objectives for Celsion's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Celsion's share price to reach $9.00 in the next year. This suggests a possible upside of 359.2% from the stock's current price. View Analyst Price Targets for Celsion. What is the consensus analysts' recommendation for Celsion? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion. Has Celsion been receiving favorable news coverage? News articles about CLSN stock have been trending somewhat positive this week, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celsion earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. Who are some of Celsion's key competitors? Some companies that are related to Celsion include Marinus Pharmaceuticals (MRNS), OASMIA PHARMACE/ADR (OASM), REDHILL BIOPHAR/S (RDHL), Emisphere Technologies (EMIS), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), VERONA PHARMA P/S (VRNA), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Northwest Biotherapeutics (NWBO), Imprimis Pharmaceuticals (IMMY), Cerecor (CERC), Ardelyx (ARDX), Adamis Pharmaceuticals (ADMP), Galmed Pharmaceuticals (GLMD), Correvio Pharma (CORV) and Menlo Therapeutics (MNLO). Who are Celsion's key executives? Celsion's management team includes the folowing people: Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 67)Mr. Jeffrey W. Church CPA, CPA, CFO, Sr. VP of Corp. Strategy & Investor Relations (Age 61)Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 58)Dr. Nicholas Borys, VP & Chief Medical Officer (Age 59)Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 60) Who are Celsion's major shareholders? Celsion's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc (3.95%) and Vanguard Group Inc. (3.95%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Michael H Tardugno and Robert W Hooper. View Institutional Ownership Trends for Celsion. Which major investors are buying Celsion stock? CLSN stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc and Vanguard Group Inc.. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Michael H Tardugno and Robert W Hooper. View Insider Buying and Selling for Celsion. How do I buy shares of Celsion? Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Celsion's stock price today? One share of CLSN stock can currently be purchased for approximately $1.96. How big of a company is Celsion? Celsion has a market capitalization of $36.71 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-20,400,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Celsion employs 21 workers across the globe. What is Celsion's official website? The official website for Celsion is http://www.celsion.com. How can I contact Celsion? Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected] MarketBeat Community Rating for Celsion (NASDAQ CLSN)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 314 (Vote Outperform)Underperform Votes: 215 (Vote Underperform)Total Votes: 529MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What is a Call Option?